This webpage has been created for internal discussions with InflaRx. Non of these videos are public.  The videos were funded in part by InflaRx Pharmaceuticals, Inc., the maker of GOHIBIC^® (vilobelimab).

The repository below provides access to the latest transcripts of the videos posted above. 

The videos were funded in part by InflaRx Pharmaceuticals, Inc., the maker of GOHIBIC^® (vilobelimab). The following references pertain to the drug:

1. Emergency Use Authorization (EUA) for Vilobelimab (IFX-1) Center for Drug Evaluation and Research (CDER) Review. SEE: https://www.fda.gov/media/167044/download?attachment
2. FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19. See https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-gohibic-vilobelimab-injection-treatment-covid-19
3. FACT SHEET FOR HEALTHCARE PROVIDERS:  EMERGENCY USE AUTHORIZATION FOR GOHIBIC. SEE: https://www.fda.gov/media/166824/download?attachment
4. Fact Sheet for Patients and Caregivers  Emergency Use Authorization (EUA) of GOHIBIC for Coronavirus Disease 2019 (COVID-19). SEE: https://www.fda.gov/media/166821/download?attachment
5. Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28. PMID: 33015643; PMCID: PMC7521913.
6. Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Dec;10(12):1137-1146. doi: 10.1016/S2213-2600(22)00297-1. Epub 2022 Sep 7. PMID: 36087611; PMCID: PMC9451499.